SuperworthBeOne Medicines ONC
- Market cap
- $42.9B
- PE
- 67.6×
- Forward PE
- 48.1×
- 10y median 58.9×
- Price to sales
- 7.0×
- EV/EBIT
- 42.2×
- Revenue, 12 months
- $6.1B
- +34% on a year ago
- Net margin
- 10.7%
- Free cash flow yield
- 3.1%
BeOne Medicines trades at 67.6× trailing earnings. Revenue was $6.1B over the last twelve months, up 34% on a year earlier with a 11% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $781.3M+102% | $634.4M+67% | $751.7M+68% | $929.2M+56% | $1B+28% | $1.1B+78% | $1.1B+49% | $1.3B+42% | $1.4B+41% | $1.5B+33% | $1.5B+36% | $1.7B+30% | |
| Cost of revenue | $96.3M+26% | $105.8M+44% | $124.9M+53% | $138.1M+44% | $170.5M+77% | $160.6M+52% | $165M+32% | $164.6M+19% | $196.5M+15% | $142.4M−11% | $167.2M+1% | $174.5M+6% |
| Gross profit | $685M+120% | $528.6M+72% | $626.7M+71% | $791M+58% | $831.1M+21% | $967.3M+83% | $952.3M+52% | $1.2B+46% | $1.2B+46% | $1.4B+40% | $1.3B+41% | $1.5B+33% |
| R&D | $453.3M+6% | $494M+11% | $460.6M+13% | $454.5M+8% | $496.2M+10% | $542M+10% | $481.9M+5% | $524.9M+16% | $523.7M+6% | $615.4M+14% | $541.2M+12% | $612.3M+17% |
| SG&A | $365.7M+13% | $418.4M+27% | $427.4M+30% | $443.7M+12% | $455.2M+25% | $504.7M+21% | $459.3M+8% | $537.9M+21% | $529M+16% | $555.3M+10% | $555.1M+21% | $593.2M+10% |
| −$134M−69% | −$383.8M−18% | −$261.3M−30% | −$107.2M−66% | −$120.3M−10% | −$79.4M−79% | $11.1M | $87.9M | $163.1M | $185M | $249.9M+2151% | $325M+270% | |
| Interest expense | $6.6M+19% | $4.7M−8% | $12.4M+171% | $13.2M+171% | $14.3M+116% | $6.9M+48% | $7M−44% | $8M−40% | $12.7M−12% | $20.6M+196% | $32.9M+370% | $39.7M+397% |
| Pre-tax income | $229.3M | −$350.8M−19% | −$243.4M−28% | −$105.9M−71% | −$98.3M | −$85.4M−76% | $20.9M | $99.5M | $147.2M | $149.2M | $259.2M+1140% | $312.5M+214% |
| $13.9M+120% | $16.8M+17% | $7.7M−33% | $14.5M+6% | $23M+66% | $66.5M+297% | $19.6M+154% | $5.2M−64% | $22.3M−3% | $82.7M+24% | $31.9M+62% | $75.5M+1343% | |
| Net income | $215.4M | −$367.6M−18% | −$251.2M−28% | −$120.4M−68% | −$121.3M | −$151.9M−59% | $1.3M | $94.3M | $124.8M | $66.5M | $227.4M+17802% | $237M+151% |
| $0.15 | −$0.27−18% | −$0.19−27% | −$0.09−68% | −$0.09 | −$0.11−59% | $0.00 | $0.06 | $0.08 | $0.04 | $0.15 | $0.16+167% | |
| 1.4B+3% | 1.4B+0% | 1.4B+0% | 1.4B+0% | 1.4B−1% | 1.4B+3% | 1.4B+7% | 1.5B+8% | 1.5B+8% | 1.5B+8% | 1.5B+4% | 1.5B+3% |
Gross profit: 25 periods, Q3 FY17 to Q3 FY23: not printed by the filing, worked out from its own lines.
EPS, diluted: 8 periods, Q4 FY15 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 10 periods, Q4 FY15 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $1.8B | $1.7B to $1.8B | $1.89 | $1.81 to $1.96 | 6 |
| Q4 FY26 | $1.8B | $1.8B to $1.8B | $1.61 | $1.51 to $1.71 | 6 |
| Q1 FY27 | $1.8B | $1.7B to $1.8B | $1.91 | $1.85 to $2.00 | 2 |
| Q2 FY27 | $1.9B | $1.9B to $2B | $2.45 | $2.36 to $2.55 | 2 |
| Q3 FY27 | $1.9B | $1.9B to $2B | $2.39 | $2.31 to $2.49 | 2 |
| Q4 FY27 | $2B | $2B to $2.1B | $3.10 | $2.99 to $3.23 | 2 |
| Q1 FY28 | $1.7B | $1.7B to $1.8B | $2.91 | $2.81 to $3.03 | 5 |
| Q2 FY28 | $1.9B | $1.8B to $1.9B | $3.47 | $3.35 to $3.61 | 5 |
Peers
Companies in Biotechnology nearest BeOne Medicines' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ONCBeOne Medicines | $42.9B | 67.6× | 68.4× | 48.1× | 7.0× | +34% | 10.7% |
| ALNYAlnylam Pharmaceuticals | $30B | 37.8× | 69.2× | 26.7× | 6.2× | +95% | 16.8% |
| UTHRUnited Therapeutics | $25.2B | 21.0× | 14.1× | 22.0× | 8.0× | +2% | 41.6% |
| INCYIncyte | $23.5B | 14.7× | 36.9× | 49.5× | 4.0× | +27% | 27.7% |
| REGNRegeneron Pharmaceuticals | $82.9B | 19.9× | 19.7× | 12.6× | 5.3× | +9% | 27.9% |
| EXELExelixis | $16B | 20.3× | 22.8× | n/m | 6.6× | +9% | 35.3% |
| NBIXNeurocrine Biosciences | $14.5B | 20.9× | 42.8× | n/m | 4.3× | +34% | 20.9% |
| HALOHalozyme Therapeutics | $14.3B | 37.5× | 21.3× | n/m | 8.6× | +41% | 24.9% |
| VRTXVertex Pharmaceuticals | $132.8B | 30.5× | 28.6× | 27.0× | 10.6× | +10% | 35.0% |
| TECHBIO-TECHNE | $11.4B | 63.1× | 61.6× | n/m | 9.4× | −0% | 15.0% |
| RGENRepligen | $10B | 242× | 120× | n/m | 12.7× | +16% | 5.3% |
| Peer median | $19.7B | 25.8× | 32.8× | 26.7× | 7.3× | +13% | 26.3% |
Investors who own it
Investors we follow who held BeOne Medicines at the end of Jun 30, 2026, from their 13F filings.
- Baillie GiffordBaillie Gifford0.0% of portfolioadded
More on BeOne Medicines
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #8of 53Healthcare stocks with the fastest expected revenue growth
- #9of 34Healthcare stocks with the lowest PEG ratio
- #10of 18Biotech stocks with the highest free cash flow yield
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .